In this segment from Thursday's Market Checkup, Motley Fool health care analysts David Williamson and Michael Douglass take a look at Catamaran (CTRX.DL) following its earnings, and discuss two reasons the pharmacy benefits management company could be set to outperform in the coming year.
First, Catamaran isn't at risk of losing any big clients, with cornerstone customer Cigna firmly in place for a decade. That means investors should be able to count on more additions than subtractions. Secondly, Gilead's (GILD 0.64%) blockbuster hepatitis C drug Sovaldi, despite its massive price tag, could actually be a tailwind for the company as its specialty pharmacy unit Briova is poised to increase revenue in a big way this year. Demand for Sovaldi should increase Briova's reach into new areas and gain new customers.
Catamaran's positive spin on Sovaldi and solid book of business are great reasons this stock should definitely be on investors' radars.
